ADPD 2026 17 - 21 March 2026

Insights into the evoke and evoke+ trials of semaglutide in early Alzheimer’s disease: A deep dive with additional data and analyses

Authors :

Jeffrey L. Cummings¹, Alireza Atri^2–4, Mary Sano^5,6, Henrik Zetterberg⁷, Philip Scheltens^8,9, Filip K. Knop¹⁰, Peter Johannsen¹⁰, Christian A Wichmann¹⁰, Rikke M. Abschneider¹⁰, Anna Areovimata¹⁰, Marie R. Sass¹⁰; Joseph Polex-Wolf¹⁰, Dylan Belmont-Rausch¹⁰, Martí Jiménez-Mausbach¹⁰, Howard H. Feldman¹¹

Affiliations

View Details Hide Details

Keywords

Alzheimer's Disease

Congress oral presentation

GLP-1 RA

Semaglutide

PHASE 3 (RCT)

Search Science Hub

Are you a healthcare professional?

Insights into the evoke and evoke+ trials of semaglutide in early Alzheimer’s disease: A deep dive with additional data and analyses